<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786017</url>
  </required_header>
  <id_info>
    <org_study_id>CAS-XDA-DC/IGDB</org_study_id>
    <nct_id>NCT02786017</nct_id>
  </id_info>
  <brief_title>Injectable Collagen Scaffold™ Combined With HUC-MSCs Transplantation for Patients With Decompensated Cirrhosis</brief_title>
  <official_title>The Safety and Efficacy Assessment of Injectable Collagen Scaffold™ Combined With Human Umbilical Cord-derived Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Patients With Decompensated Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of injectable collagen
      scaffold combined with human umbilical cord-derived mesenchymal stem cells (HUC-MSCs)
      transplantation in patients with Decompensated Cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of liver function measured by change in the model for end-stage liver disease (MELD) score</measure>
    <time_frame>1 week, 2 week, 1, 3, 6, 12, 24 month after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of liver function measured by change in Child-Pugh score</measure>
    <time_frame>1 week, 2 week, 1, 3, 6, 12, 24 month after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical laboratory parameters of liver function</measure>
    <time_frame>1 day, 3 day, 1 week, 2 week, 1, 3, 6, 12, 24 month after intervention</time_frame>
    <description>The liver function tests included serum Albumin (Alb), Cholesterol, Cholinesterase (CHE), prothrombin activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-Day Survival</measure>
    <time_frame>30 days</time_frame>
    <description>Patients surviving more than 30 days after study registration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the size of liver and spleen and inner diameter of spleen portal venous</measure>
    <time_frame>1 week, 2 week, 1, 3, 6, 12, 24 month after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Decompensated Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Conventional therapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Injectable Collagen Scaffold + HUC-MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conventional therapy</intervention_name>
    <description>Patients will receive the conventional therapy.</description>
    <arm_group_label>Conventional therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injectable Collagen Scaffold + HUC-MSCs</intervention_name>
    <description>Injectable collagen scaffold combined with HUC-MSCs was injected into left lateral segment, left medial segment, right anterior segment, right posterior segment and caudate lobe under B-mode ultrasound supervision, respectively. The total amount of HUC-MSCs was 5*10^8.</description>
    <arm_group_label>Injectable Collagen Scaffold + HUC-MSCs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must meet all of the following criteria:

          1. Subjects who are decompensated cirrhosis of any cause.

          2. Subjects are repeated exacerbations despite treatment and hospitalized more than once
             within one year because of complications of cirrhosis, (e.g., massive ascites,
             spontaneous bacterial peritonitis, gastrointestinal bleeding or hepatic
             encephalopathy).

          3. Need intermittent plasma albumin and oral diuretics supplement.

          4. Serum albumin &lt;35 g/L, total bilirubin&lt;170 μmol/L, prothrombin activity &gt;30%
             (prothrombin time &lt;20 s), moderate or mild ascites, spontaneous bacterial peritonitis
             and hepatic encephalopathy have been cured, Child-pugh score ≥7.

          5. Peripheral blood hemoglobin concentration&gt; 70g/L，platelet count &gt; 3 × 10^9/L,
             hematocrit (HCT) level&gt;0.25.

          6. No gastrointestinal bleeding during the last one month before enrolment.

          7. Patient has no conditional to undergo orthotopic liver transplantation (OLT).

          8. Willing to sign informed consent.

        Exclusion Criteria:

        Participants CANNOT meet any of the following criteria:

          1. The presence of hepatocellular carcinoma (HCC) or other malignant tumors.

          2. Complicated with gastrointestinal bleeding, spontaneous bacterial peritonitis, hepatic
             encephalopathy, hepatorenal syndrome and acute exacerbation of infection.

          3. Presence of severe comorbid diseases (e.g., severe renal, respiratory, cardiac or
             blood disease).

          4. Pregnant or lactating women.

          5. Allergy to G-CSF, contrast agents and anticoagulants.

          6. Alcoholism or drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianwu Dai, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhifeng Xiao, Ph.D</last_name>
    <phone>86-10-82614420</phone>
    <email>zfxiao@genetics.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sufang Han, Ph.D</last_name>
    <phone>86-10-82614420</phone>
    <email>sufanghan22@genetics.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaolei Shi, M.D.</last_name>
      <phone>86-25-83304616</phone>
      <phone_ext>11901</phone_ext>
      <email>njsxl2000@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2016</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Jianwu Dai</investigator_full_name>
    <investigator_title>Principal Investigator of Regenerative Medicine Laboratory, Institute of Genetics and Developmental Biology, CAS</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

